EndoPredict accurately predicts early recurrence by including proliferation-related genes and late recurrence with hormone receptor–related genes.

  • 2nd generation prognostic tests include genes that predict both early and late recurrence
  • Early recurrence is defined as a recurrence that occurs within the first 5 years after initial diagnosis
  • Late recurrence is defined as a recurrence that occurs more than 5 years after initial diagnosis
  • Women with ER+ disease face a relatively consistent risk of disease recurrence well beyond 5 years. Up to 50% of breast cancer recurrences occur beyond 5 years post diagnosis (ref).
  • While deaths from ER− breast cancer peak early and taper off significantly, individuals with ER+ breast cancer face a mild early peak without a significant risk reduction continuing through 12 years after diagnosis.
  • Identification of women with low long-term risk of recurrence can help identify more women who may safely forgo chemotherapy.
  • EndoPredict was trained and validated on 10-year clinical outcomes